Stem Cell Therapy for Retinal Degeneration: The Evidence to Date
Amit Sharma,Bithiah Grace Jaganathan
DOI: https://doi.org/10.2147/BTT.S290331
2021-07-27
Biologics: Targets and Therapy
Abstract:Amit Sharma, Bithiah Grace Jaganathan Stem Cells and Cancer Biology Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India Correspondence: Bithiah Grace Jaganathan Stem Cells and Cancer Biology Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India Tel +91 361 258 2219 Email There is a rise in the number of people who have vision loss due to retinal diseases, and conventional therapies for treating retinal degeneration fail to repair and regenerate the damaged retina. Several studies in animal models and human trials have explored the use of stem cells to repair the retinal tissue to improve visual acuity. In addition to the treatment of age-related macular degeneration (AMD) and diabetic retinopathy (DR), stem cell therapies were used to treat genetic diseases such as retinitis pigmentosa (RP) and Stargardt's disease, characterized by gradual loss of photoreceptor cells in the retina. Transplantation of retinal pigment epithelial (RPE) cells derived from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have shown promising results in improving retinal function in various preclinical models of retinal degeneration and clinical studies without any severe side effects. Mesenchymal stem cells (MSCs) were utilized to treat optic neuropathy, RP, DR, and glaucoma with positive clinical outcomes. This review summarizes the preclinical and clinical evidence of stem cell therapy and current limitations in utilizing stem cells for retinal degeneration. Keywords: retinal degeneration, retinal pigment epithelial cells, mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, retinitis pigmentosa Graphical Retinal degeneration is one of the major reasons for vision loss, and stem cell therapy has been extensively investigated to repair and regenerate damaged retinal cells. Several types of stem cells have been tested in preclinical and clinical trials to understand their efficiency in reversing retinal degeneration. To date, human embryonic stem cells (hESCs)-, induced pluripotent stem cells (iPSCs)-derived RPE cells, mesenchymal stem cells (MSCs) and retinal progenitor cells (RPCs) have been tested in addition to paracrine factors and exosomes derived from MSCs. Conventional therapies for retinal diseases slow the progression of the diseases; however, the long-term benefit is achieved by repairing and regenerating the damaged retinal tissue. Moreover, since the retina does not have intrinsic regenerative properties, stem cell therapies have been sought to repair and regenerate the damaged retina. 1 Several preclinical and clinical studies have demonstrated that transplantation of stem cells and factors derived from stem cells produce clinically measurable improvement. This review will discuss the different stem cells utilized to treat retinal diseases and the clinical benefits and challenges in utilizing stem cells to treat retinal degeneration. The etiology of retinal degenerative diseases includes genetic and non-genetic factors leading to the loss of photoreceptor cells and eventually the RPE cells. Age-related macular degeneration (AMD) is one of the most common forms of vision loss, which might either be due to degradation of RPE cells (dry AMD) or choroidal neovascularization (wet AMD). Wet AMD is treated with anti-VEGF therapy, which can lead to clinical improvement in vision. 2 , 3 In contrast, fewer therapeutic options are available to improve the vision in patients with dry AMD. Retinitis pigmentosa (RP) occurs due to autosomal 4 or X-linked mutations, which contribute to the degeneration of photoreceptors leading to vision loss. FDA-approved therapeutic interventions for RP include gene therapy for patients with a biallelic mutation in RPE65 5 and retinal prosthesis for late-stage RP. 6 Diabetic retinopathy (DR) is caused due to chronic hyperglycemia and is treated with anti-VEGF to limit the neovascularization at the proliferative stage or late-stage DR. 7 Although these conventional therapies have improved the disease prognosis, repeated administration is required to diminish the disease progression, and gene therapy is applicable only for those patients with vision loss due to specific mutations. Stem cells were tested in several clinical trials, and the approaches include transplantation of undifferentiated stem cells, pre-differentiated stem cells, or stem cell-derived factors. Several studies and clinical trials have utilized RPE cells derived from hES -Abstract Truncated-